See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
AstraZeneca PLC (AZN) - free report >>
GSK PLC Sponsored ADR (GSK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca PLC (AZN) - free report >>
GSK PLC Sponsored ADR (GSK) - free report >>
Image: Bigstock
Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma
Positive news flowed in at Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) when the European Commission approved its marketing authorisation application for Cinqaero (reslizumab; interleukin-5 (IL-5) antagonist monoclonal antibody) for use as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
The EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this June.
The company expects to make Cinqaero commercially available in Europe within a few upcoming months. We remind investors that Cinqaero is already marketed in the U.S. and Canada under the trade name Cinqair. Regulatory applications in other global markets are, however, pending.
TEVA PHARM ADR Price
TEVA PHARM ADR Price | TEVA PHARM ADR Quote
We note that GlaxoSmithKline plc’s (GSK - Free Report) Nucala, another IL-5 antagonist monoclonal antibody, is marketed in both the U.S. and the EU. Meanwhile, companies like AstraZeneca plc (AZN - Free Report) are also looking to bring their anti-IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD).
Meanwhile, Teva has several programs ranging from phase I to registration in its pipeline with many of these focused on the central nervous system and the respiratory system (asthma, COPD and allergic rhinitis). As far as other therapeutic areas like women’s health and oncology are concerned, Teva is focusing on market-ready or close-to-market products to maximize sustainable profitability.
Teva is a Zacks Rank #3 (Hold) stock. Anika Therapeutics Inc. (ANIK - Free Report) is a better-ranked stock in the healthcare sector, sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>